View Future GrowthBioceltix 과거 순이익 실적과거 기준 점검 0/6Bioceltix의 수입은 연평균 -24.1%의 비율로 감소해 온 반면, Biotechs 산업의 수입은 연간 13.3% 증가했습니다.핵심 정보-24.05%순이익 성장률-13.26%주당순이익(EPS) 성장률Biotechs 산업 성장률56.32%매출 성장률n/a자기자본이익률-56.25%순이익률n/a다음 순이익 업데이트29 May 2026최근 과거 실적 업데이트공시 • Aug 27Bioceltix S.A. to Report First Half, 2025 Results on Sep 30, 2025Bioceltix S.A. announced that they will report first half, 2025 results on Sep 30, 2025공시 • Jan 24+ 3 more updatesBioceltix S.A. to Report Fiscal Year 2023 Results on Apr 26, 2024Bioceltix S.A. announced that they will report fiscal year 2023 results on Apr 26, 2024공시 • Jan 12+ 3 more updatesBioceltix S.A. to Report Q3, 2023 Results on Nov 21, 2023Bioceltix S.A. announced that they will report Q3, 2023 results on Nov 21, 2023공시 • Sep 10Bioceltix S.A. to Report First Half, 2022 Results on Sep 27, 2022Bioceltix S.A. announced that they will report first half, 2022 results on Sep 27, 2022모든 업데이트 보기Recent updatesNew Risk • May 17New major risk - Revenue and earnings growthEarnings have declined by 26% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (zł11m net loss in 2 years).New Risk • Mar 20New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: zł368.4m (US$99.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (zł11m net loss in 2 years). Market cap is less than US$100m (zł368.4m market cap, or US$99.5m).분석 기사 • Dec 11We Think Bioceltix (WSE:BCX) Can Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...New Risk • Sep 15New major risk - Revenue and earnings growthEarnings have declined by 34% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m.공시 • Aug 27Bioceltix S.A. to Report First Half, 2025 Results on Sep 30, 2025Bioceltix S.A. announced that they will report first half, 2025 results on Sep 30, 2025New Risk • Jun 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable next year (zł6.5m net loss next year). Share price has been volatile over the past 3 months (7.4% average weekly change). Shareholders have been diluted in the past year (19% increase in shares outstanding).공시 • May 21Bioceltix S.A., Annual General Meeting, Jun 16, 2025Bioceltix S.A., Annual General Meeting, Jun 16, 2025.분석 기사 • Mar 05We're Not Very Worried About Bioceltix's (WSE:BCX) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...New Risk • Aug 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł14m free cash flow). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (zł356.5m market cap, or US$90.4m).New Risk • Jul 07New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 19% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł14m free cash flow). Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (zł312.7m market cap, or US$79.2m).분석 기사 • Jun 15We're Keeping An Eye On Bioceltix's (WSE:BCX) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, although...공시 • Jun 01Bioceltix S.A., Annual General Meeting, Jun 26, 2024Bioceltix S.A., Annual General Meeting, Jun 26, 2024, at 11:00 Central European Standard Time.공시 • Jan 24+ 3 more updatesBioceltix S.A. to Report Fiscal Year 2023 Results on Apr 26, 2024Bioceltix S.A. announced that they will report fiscal year 2023 results on Apr 26, 2024분석 기사 • Jan 19Will Bioceltix (WSE:BCX) Spend Its Cash Wisely?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...분석 기사 • Sep 21We're Keeping An Eye On Bioceltix's (WSE:BCX) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...공시 • Jun 02Bioceltix S.A., Annual General Meeting, Jun 27, 2023Bioceltix S.A., Annual General Meeting, Jun 27, 2023, at 12:00 Central European Standard Time.분석 기사 • May 09We're Keeping An Eye On Bioceltix's (WSE:BCX) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, Bioceltix ( WSE:BCX...공시 • Jan 12+ 3 more updatesBioceltix S.A. to Report Q3, 2023 Results on Nov 21, 2023Bioceltix S.A. announced that they will report Q3, 2023 results on Nov 21, 2023공시 • Sep 10Bioceltix S.A. to Report First Half, 2022 Results on Sep 27, 2022Bioceltix S.A. announced that they will report first half, 2022 results on Sep 27, 2022공시 • Jul 19Bioceltix S.A. announced that it expects to receive PLN 4.21608 million in fundingBioceltix S.A. announced a private placement of 140,536 common shares at the price of KRW 1,310 per share for gross proceeds of 4.21608 million on July 18, 2022.공시 • May 21Bioceltix S.A., Annual General Meeting, Jun 15, 2022Bioceltix S.A., Annual General Meeting, Jun 15, 2022, at 12:00 Central European Standard Time.매출 및 비용 세부 내역Bioceltix가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이WSE:BCX 매출, 비용 및 순이익 (PLN Millions)날짜매출순이익일반관리비연구개발비31 Dec 250-150030 Sep 250-1515030 Jun 250-1414031 Mar 250-1416031 Dec 240-1516030 Sep 240-1616030 Jun 240-1617031 Mar 240-1516031 Dec 230-1414030 Sep 230-1312030 Jun 230-1211031 Mar 230-109031 Dec 220-98030 Sep 220-87030 Jun 220-55031 Mar 220-550양질의 수익: BCX 은(는) 현재 수익성이 없습니다.이익 마진 증가: BCX는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: BCX은 수익성이 없으며 지난 5년 동안 손실이 연평균 24.1% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 BCX의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: BCX은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(39.9%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: BCX는 현재 수익성이 없으므로 자본 수익률이 음수(-56.25%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/26 03:36종가2026/05/26 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Bioceltix S.A.는 1명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Beata Szparaga-WasniewskaBiuro maklerskie mBanku
공시 • Aug 27Bioceltix S.A. to Report First Half, 2025 Results on Sep 30, 2025Bioceltix S.A. announced that they will report first half, 2025 results on Sep 30, 2025
공시 • Jan 24+ 3 more updatesBioceltix S.A. to Report Fiscal Year 2023 Results on Apr 26, 2024Bioceltix S.A. announced that they will report fiscal year 2023 results on Apr 26, 2024
공시 • Jan 12+ 3 more updatesBioceltix S.A. to Report Q3, 2023 Results on Nov 21, 2023Bioceltix S.A. announced that they will report Q3, 2023 results on Nov 21, 2023
공시 • Sep 10Bioceltix S.A. to Report First Half, 2022 Results on Sep 27, 2022Bioceltix S.A. announced that they will report first half, 2022 results on Sep 27, 2022
New Risk • May 17New major risk - Revenue and earnings growthEarnings have declined by 26% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (zł11m net loss in 2 years).
New Risk • Mar 20New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: zł368.4m (US$99.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (zł11m net loss in 2 years). Market cap is less than US$100m (zł368.4m market cap, or US$99.5m).
분석 기사 • Dec 11We Think Bioceltix (WSE:BCX) Can Afford To Drive Business GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
New Risk • Sep 15New major risk - Revenue and earnings growthEarnings have declined by 34% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m.
공시 • Aug 27Bioceltix S.A. to Report First Half, 2025 Results on Sep 30, 2025Bioceltix S.A. announced that they will report first half, 2025 results on Sep 30, 2025
New Risk • Jun 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable next year (zł6.5m net loss next year). Share price has been volatile over the past 3 months (7.4% average weekly change). Shareholders have been diluted in the past year (19% increase in shares outstanding).
공시 • May 21Bioceltix S.A., Annual General Meeting, Jun 16, 2025Bioceltix S.A., Annual General Meeting, Jun 16, 2025.
분석 기사 • Mar 05We're Not Very Worried About Bioceltix's (WSE:BCX) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
New Risk • Aug 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł14m free cash flow). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (zł356.5m market cap, or US$90.4m).
New Risk • Jul 07New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 19% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł14m free cash flow). Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (19% increase in shares outstanding). Market cap is less than US$100m (zł312.7m market cap, or US$79.2m).
분석 기사 • Jun 15We're Keeping An Eye On Bioceltix's (WSE:BCX) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, although...
공시 • Jun 01Bioceltix S.A., Annual General Meeting, Jun 26, 2024Bioceltix S.A., Annual General Meeting, Jun 26, 2024, at 11:00 Central European Standard Time.
공시 • Jan 24+ 3 more updatesBioceltix S.A. to Report Fiscal Year 2023 Results on Apr 26, 2024Bioceltix S.A. announced that they will report fiscal year 2023 results on Apr 26, 2024
분석 기사 • Jan 19Will Bioceltix (WSE:BCX) Spend Its Cash Wisely?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • Sep 21We're Keeping An Eye On Bioceltix's (WSE:BCX) Cash Burn RateJust because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
공시 • Jun 02Bioceltix S.A., Annual General Meeting, Jun 27, 2023Bioceltix S.A., Annual General Meeting, Jun 27, 2023, at 12:00 Central European Standard Time.
분석 기사 • May 09We're Keeping An Eye On Bioceltix's (WSE:BCX) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, Bioceltix ( WSE:BCX...
공시 • Jan 12+ 3 more updatesBioceltix S.A. to Report Q3, 2023 Results on Nov 21, 2023Bioceltix S.A. announced that they will report Q3, 2023 results on Nov 21, 2023
공시 • Sep 10Bioceltix S.A. to Report First Half, 2022 Results on Sep 27, 2022Bioceltix S.A. announced that they will report first half, 2022 results on Sep 27, 2022
공시 • Jul 19Bioceltix S.A. announced that it expects to receive PLN 4.21608 million in fundingBioceltix S.A. announced a private placement of 140,536 common shares at the price of KRW 1,310 per share for gross proceeds of 4.21608 million on July 18, 2022.
공시 • May 21Bioceltix S.A., Annual General Meeting, Jun 15, 2022Bioceltix S.A., Annual General Meeting, Jun 15, 2022, at 12:00 Central European Standard Time.